Engrail Raises $32 Million From China Investors for CNS Drug Program

Engrail Therapeutics™, a San Diego neuroscience company, closed a $32 million  extension of its Series A financing from Nan Fung Life Sciences of Hong Kong. In addition, NFLS made a long-term commitment to invest $2 billion in the life science sector, which will enable Engrail to acquire assets with validated mechanisms for nervous system diseases. Engrail is open to licensing, co-development and acquisition deals. It acquires products while also developing candidates in-house. With the $32 million, the total raised in the Series A is now $64 million. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.